E. Granzer

603 citations
29 papers · 478 indexed · h-index 12

E. Granzer

27 papers receiving 417 citations

Peers

E. Granzer
Comparison fields: 5 of 78
  • Biotechnology 87
  • Pharmacology 121
  • Organic Chemistry 189
  • Microbiology 4
  • Biochemistry 23
Replace E. Baader with:
E. Baader Germany
HAMAO UMEZAWA Japan
Randall R. Rossman United States
Alberto Bargiotti Italy
MOTOAKI NISHIKAWA Japan
Suk Kyoon Yoon South Korea
David J. Madar United States
Ermes Vanotti Italy
Catherine Sekerke United States
J. J. Godfroid France
E. Granzer relative to E. Baader Germany E. Baader's profile →
Citations per field
00.5×1.5×
E. Baader · 1×
Citations per year

Countries citing papers authored by E. Granzer

Since Specialization
Citations

This map shows the geographic impact of E. Granzer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Granzer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Granzer more than expected).

Fields of papers citing papers by E. Granzer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Granzer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Granzer. The network helps show where E. Granzer may publish in the future.

Co-authorship network

The 25 scholars most cited alongside E. Granzer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with E. Granzer Line = papers co-authored together E. Granzer links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 1992113
2 199143
3 199057
4 199048
5 198812
6 19879
7 198613
8
[Lipoprotein regulatory effect of molsodomine in rats].
19841
9
HCG 004, a new highly potent hypolipidaemic drug.
19735
10 19721
11 197011
12 19661
13 196413
14 19644
15 19636
16 196228
17 196229
18 196215
19 196021
20 19525

About E. Granzer

E. Granzer is a scholar working on Biochemistry, Organic Chemistry and Pharmacology, having authored 29 papers that have together received 478 indexed citations. Recurring topics across this work include Glycosylation and Glycoproteins Research (3 papers), Computational Drug Discovery Methods (3 papers), Inflammatory mediators and NSAID effects (3 papers), Amino Acid Enzymes and Metabolism (2 papers), Synthesis and biological activity (2 papers), Analytical Chemistry and Chromatography (2 papers), Erythrocyte Function and Pathophysiology (2 papers) and Synthesis and Reactivity of Sulfur-Containing Compounds (2 papers). The work is most often cited by research in Biotechnology (87 citations), Pharmacology (121 citations) and Organic Chemistry (189 citations). E. Granzer has collaborated with scholars based in Germany, Switzerland and Austria. Frequent co-authors include G. Ruhenstroth‐Bauer, G. Beck, B. v. Kerékjártó, Heiner Jendralla, Wilhelm Bartmann, E. Baader, R. A. Krause, Andreas Bergmann, Günter Fred Fuhrmann and Kurt Keßeler. Their work appears in journals such as Die Naturwissenschaften, Journal of Medicinal Chemistry, Tetrahedron Letters, Cellular and Molecular Life Sciences and The Journal of Antibiotics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026